Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer. Materials and Methods Patients were treated with irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity. Results A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the perprotocol group was 30.0% (90% confidence interval [CI], 13.2 to 46.9). The median followup duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%). Conclusion Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer.
Abstract
Purpose The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer. Materials and Methods Patients were treated with irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity. Results A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the perprotocol group was 30.0% (90% confidence interval [CI], 13.2 to 46.9). The median followup duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%). Conclusion Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer.
참고문헌 (20)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Pennathur A, "Oesophageal carcinoma", Lancet, 381, pp.400~412 (2013)
- Bleiberg H, "Randomised phase II study of cisplatin and 5-fluorouracil(5-FU)versus cisplatin alone in advanced squamous cell oesophageal cancer", Eur J Cancer, 33, pp.1216~1220 (1997)
- Muhr-Wilkenshoff F, "A pilot study of irinotecan(CPT-11)as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma", Int J Colorectal Dis, 18, pp.330~334 (2003)
- Enzinger PC, "A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma", Dig Dis Sci, 50, pp.2218~2223 (2005)
- Wolff K, "Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid(AIO regimen)plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus : a phase II trial", Anticancer Drugs, 20, pp.165~173 (2009)
- Enzinger PC, "Weekly docetaxel, cisplatin, and irinotecan(TPC) : results of a multicenter phase II trial in patients with metastatic esophagogastric cancer", Ann Oncol, 20, pp.475~480 (2009)
- Lee DH, "A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus", Cancer Chemother Pharmacol, 61, pp.83~88 (2008)
- Ilson DH, "Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer", J Clin Oncol, 17, pp.3270~3275 (1999)
- Assersohn L, "Phase II study of irinotecan and 5-fluorouracil", leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, 2004, pp.15, 64~69
- Burtness B, "Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer", Ann Oncol, 20, pp.1242~1248 (2009)
- Ilson DH, "Phase II trial of weekly irinotecan", cisplatin in advanced esophageal cancer, 2004, pp.18(14 Suppl 14), 22~25
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Elliott JA, "Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma", Br J Surg, 101, pp.1702~1711 (2014)
- Tamandl D, "Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer", Eur Radiol, 26, pp.311~321 (2016)
- Pan L, "Prognostic significance of SUV on PET", CT in patients with esophageal cancer : a systematic review and meta-analysis, 2009, pp.21, 1008~1015
- Gillies RS, "Metabolic response at repeat PET", CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer, 2012, pp.22, 2035~2043
- Kukar M, "Role of repeat 18F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma", JAMA Surg, 150, pp.555~562 (2015)
- Shimoyama S, "Pharmacogenetics of irinotecan : An ethnicitybased prediction of irinotecan adverse events", World J Gastrointest Surg, 2, pp.14~21 (2010)